These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25417463)

  • 21. Latency reversal and viral clearance to cure HIV-1.
    Margolis DM; Garcia JV; Hazuda DJ; Haynes BF
    Science; 2016 Jul; 353(6297):aaf6517. PubMed ID: 27463679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.
    Yu W; Liu J; Yu Y; Zhang V; Clausen D; Kelly J; Wolkenberg S; Beshore D; Duffy JL; Chung CC; Myers RW; Klein DJ; Fells J; Holloway K; Wu J; Wu G; Howell BJ; Barnard RJO; Kozlowski J
    Bioorg Med Chem Lett; 2020 Jul; 30(13):127197. PubMed ID: 32331932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutics for HIV-1 reactivation from latency.
    Sgarbanti M; Battistini A
    Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV: Shock and kill.
    Deeks SG
    Nature; 2012 Jul; 487(7408):439-40. PubMed ID: 22836995
    [No Abstract]   [Full Text] [Related]  

  • 26. Progress and challenges in the use of latent HIV-1 reactivating agents.
    Shang HT; Ding JW; Yu SY; Wu T; Zhang QL; Liang FJ
    Acta Pharmacol Sin; 2015 Aug; 36(8):908-16. PubMed ID: 26027656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.
    Shehu-Xhilaga M; Rhodes D; Wightman F; Liu HB; Solomon A; Saleh S; Dear AE; Cameron PU; Lewin SR
    AIDS; 2009 Sep; 23(15):2047-50. PubMed ID: 19609198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials.
    Prince HM
    Leuk Lymphoma; 2012 Sep; 53(9):1658-9. PubMed ID: 22260164
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panobinostat (Farydak) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884
    [No Abstract]   [Full Text] [Related]  

  • 31. Panobinostat approved for multiple myeloma.
    Cancer Discov; 2015 May; 5(5):OF4. PubMed ID: 25802326
    [No Abstract]   [Full Text] [Related]  

  • 32. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
    Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
    J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
    Vignesh R; Shankar EM
    EBioMedicine; 2017 Oct; 24():20-21. PubMed ID: 28865747
    [No Abstract]   [Full Text] [Related]  

  • 34. The potential role for romidepsin as a component in early HIV-1 curative efforts.
    Gunst JD; Tolstrup M; Rasmussen TA; Søgaard OS
    Expert Rev Anti Infect Ther; 2016; 14(5):447-50. PubMed ID: 26953620
    [No Abstract]   [Full Text] [Related]  

  • 35. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
    Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.
    Jønsson KL; Tolstrup M; Vad-Nielsen J; Kjær K; Laustsen A; Andersen MN; Rasmussen TA; Søgaard OS; Østergaard L; Denton PW; Jakobsen MR
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3984-94. PubMed ID: 25896701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy.
    McMahon DK; Zheng L; Cyktor JC; Aga E; Macatangay BJ; Godfrey C; Para M; Mitsuyasu RT; Hesselgesser J; Dragavon J; Dobrowolski C; Karn J; Acosta EP; Gandhi RT; Mellors JW
    J Infect Dis; 2021 Aug; 224(4):648-656. PubMed ID: 34398236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic cancer therapies emerge out of the lab into the limelight.
    Wolfson W
    Chem Biol; 2013 Apr; 20(4):455-6. PubMed ID: 23601631
    [No Abstract]   [Full Text] [Related]  

  • 40. Histone deactylase inhibitor SAHA induces a synergistic HIV-1 reactivation by 12-O-tetradecanoylphorbol-13-acetate in latently infected cells.
    Park SY; Kim KC; Hong KJ; Kim SS; Choi BS
    Intervirology; 2013; 56(4):242-8. PubMed ID: 23735807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.